ReviewInternal and emergency medicine2026
Apixaban vs rivaroxaban for venous thromboembolism: a systematic review and meta-analysis.
Review in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct oral anticoagulants are first-line therapy for venous thromboembolism (VTE), yet comparative evidence between apixaban and rivaroxaban remains limited. This systematic review and meta-analysis aimed to compare the efficacy and safety of apixaban versus rivaroxaban in patients with VTE. A systematic search of PubMed, Scopus, Web of Science, and Cochrane Library was conducted from inception through March 2026. Studies directly comparing apixaban and rivaroxaban in adult VTE patients were included. Outcomes, including recurrent VTE, major bleeding, all-cause mortality, and net clinical harm, were pooled using a random-effects model. Thirteen studies comprising more than 220,000 patients were included. Apixaban was associated with a significantly lower risk of recurrent VTE compared to rivaroxaban (RR 0.85; 95% CI 0.74-0.98), with moderate heterogeneity. Apixaban was also associated with a significant 28% reduction in major bleeding risk (RR 0.72; 95% CI 0.65-0.81), with low heterogeneity, indicating consistent findings across studies. When efficacy and safety outcomes were combined, apixaban demonstrated a significantly lower risk of net clinical harm (RR 0.76; 95% CI 0.68-0.86). In contrast, no statistically significant difference was observed in all-cause mortality (RR 0.95; 95% CI 0.80-1.12), with substantial heterogeneity across studies. Sensitivity analyses confirmed the robustness of these findings, with no single study significantly altering the overall estimates. Overall, apixaban demonstrated a more favorable efficacy and safety profile compared with rivaroxaban in VTE management, with reduced recurrence and bleeding risk, while mortality remained comparable. These findings suggest that apixaban may be associated with a more favorable efficacy and safety profile than rivaroxaban; however, the results should be interpreted cautiously given the predominance of observational evidence.
Indexed as
Identifiers
42855613What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.